Navigation Links
NIAID to fund new human immune profiling research centers

The National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health, is accepting grant applications for a new initiative to establish a consortium of human immune profiling research centers. The purpose of these cooperative centerswhich together will receive funding up to $100 million over five yearsis to characterize the human immune system under normal conditions and to understand how it changes following infection or vaccination.

NIAID will launch this new research initiative in 2010, with the funding for the first year of the initiative coming from the American Recovery and Reinvestment Act.

"By helping us understand what constitutes a normal human immune response, this program will assist researchers who are developing vaccines and other interventions for a variety of infectious diseases of public health importance, including influenza, malaria, tuberculosis and HIV/AIDS," says NIAID Director Anthony S. Fauci, M.D.

Researchers will examine various elements of the immune systemincluding white blood cell subsets, signaling molecules and antibodiesafter exposure to either infectious agents such as viruses or bacteria or to the components of a vaccine, including vaccine boosters known as adjuvants. They also will follow immune responses as they return to a resting state. By doing so, immunologists can identify specific patterns of the various subsets of white blood cells and immune molecules that reflect the status and function of the immune system under different conditions.

A significant challenge for immunologists is to understand how the immune system behaves at rest, also known as homeostasis. A state of immunological homeostasis does not reflect a lack of immunologic activity, or even a restful condition. Furthermore, the immune system of an individual may return to one of several homeostatic states, depending on the nature of the particular immune challenge, such as infection or vaccination.

Although studies in mice have helped advance the understanding of immunological mechanisms, they have several limitations, and findings in animals cannot always be extrapolated to humans. In the new initiative, researchers will analyze samples from well-characterized human cohorts, such as people enrolled in clinical trials, children receiving routine vaccinations, and people with naturally acquired infections. These cohorts will represent the diversity of human populations with respect to genetics, age, ethnicity and gender.

The new program will exploit research approaches that have only recently become available such as systems biology, which integrates information about an organism's genes, proteins and metabolism with data from the host.

In addition, the initiative will provide support for centralized infrastructure to collect, characterize, and store the human samples; for bioinformatic capacity to analyze the large and complex data sets that will be generated; and for the discovery and development of new immune response monitoring tools and sample-sparing assays.

"The observations made and the new methodologies developed by investigators within this program will assist clinical research in vaccine development and beyond," says Daniel Rotrosen, M.D., director of the Division of Allergy, Immunology and Transplantation at NIAID. "These research centers are part of NIAID's long-range goal to identify the principles of human immune regulation, and then apply that knowledge to understanding, treating and preventing immune-mediated and infectious diseases."


Contact: Julie Wu
NIH/National Institute of Allergy and Infectious Diseases

Related medicine news :

1. NIAID media availability: Still searching for predictors of asthma attacks
2. NIAID set to launch clinical trials to test 2009 H1N1 influenza vaccine candidates
3. NIAID media availability: New strategy proposed for designing antibody-based HIV vaccine
4. J. Craig Venter Institute Awarded $43 Million, Five Year Contract From NIAID to Continue to Develop and Provide Sequencing, Genotyping, and Bioinformatics Expertise and Services in Infectious Diseases
5. NIAID and Chinese officials sign agreement to foster TB research in Chinas Henan province
6. NIAID honors AIDS activist Martin Delaney
7. NIAID media availability: Seizures following parasitic infection associated with brain swelling
8. NIAID awards contracts to search for protein markers of disease
9. NIAID creates HIV vaccine discovery branch
10. NIAID to advance B-cell approach to HIV vaccines
11. NIAID describes research priorities to fight drug-resistant tuberculosis
Post Your Comments:
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin ... companies that call for a minimum wage raise to $12 an hour by 2020 and ... This will restore the lost value of the minimum wage, assure the wage floor does ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: